Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the fda-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: A new hypothesis to an old question

Clinical and Translational Oncology

Volumn 11, Issue 7, 2009, Pages 408-410

  Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; MORPHOLINE DERIVATIVE;

CEREBELLUM DISEASE; CEREBELLUM TUMOR; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; NOTE; PATHOLOGY; UNITED STATES;

ANTIEMETICS; CEREBELLAR DISEASES; CEREBELLAR NEOPLASMS; GLIOBLASTOMA; HUMANS; MORPHOLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73349109802     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0379-x     Document Type: Article

References (38)

1. Grahovac G, Tomac D, Lambasa S et al (2009) Cerebellar glioblastomas: Pathophysiology, clinical presentation and management. Acta Neurochir (Wien) Mar 25 [Epub ahead of print]
2. Luccarelli G (1980) Glioblastoma multiforme of the cerebellum: Description of three cases. Acta Neurochir (Wien) 53:107-116
3. Hur H, Jung S, Jung TY, Kim IY (2008) Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc 43:194-197
4. Muñoz M, Rosso M (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs Jan 17 [Epub ahead of print]
5. Ekinci N, Acer N, Akkaya A et al (2008) Volumetric evaluation of the relations among the cerebrum, cerebellum and brain stem in young subjects: A combination of stereology and magnetic resonance imaging. Surg Radiol Anat 30:489-494
6. Del Fiacco M, Perra MT, Quartu M et al (1988) Evidence for the presence of substance P-like immunoreactivity in the human cerebellum. Brain Res 446:173-177
7. Hayashi M (1987) Ontogeny of glutamic acid decarboxylase, tyrosine hydroxylase, choline acetyltransferase, somatostatin and substance P in monkey cerebellum. Brain Res 429:181-186
8. Kwong WH, Chan WY, Lee KK et al (2000) Neurotransmitters, neuropeptides and calcium binding proteins in developing human cerebellum: A review. Histochem J 32:521-534
9. Yamashita A, Shimizu K, Hayashi M (1990) Ontogeny of substance P immunoreactive structures in the primate cerebral neocortex. Brain Res Dev Brain Res 57:197-207
10. Herpfer I, Lieb K (2005) Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential. CNS Drugs 19:275-293
11. Navari RM (2004) Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4:715-724
12. Navari RM (2004) Role of neurokinin-1 receptor antagonists in chemotherapy induced emesis: Summary of clinical trials. Cancer Invest 22:569-576
13. Yamaguchi K, Richardson MD, Bigner DD, Kwatra MM (2005) Signal transduction through substance P receptor in human glioblastoma cells: Roles for Src and PKCdelta. Cancer Chemother Pharmacol 56:585-593
14. Yamaguchi K, Kugimiya T, Miyazaki T (2005) Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src. Brain Tumor Pathol 22:1-8
15. Caberlotto L, Hurd YL, Murdock P et al (2003) Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 17:1736-1746
16. Nyman MJ, Eskola O, Kajander J et al (2007) Gender and age affect NK1 receptors in the human brain-a positron emission tomography study with [18F]SPARQ. Int J Neuropsychopharmacol 10:219-229
17. Lazarczyk M, Matyja E, Lipkowski A (2007) Substance P and its receptors-a potential target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol 45:99-107
18. Palma C, Maggi CA (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67:985-1001
19. Lopez-Gines C, Gil-Benso R, Benito R et al (2008) The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 28:507-515
20. Park SW, Yan YP, Satriotomo I et al (2007) Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg 107:593-599
21. Wiltrout C, Lang B, Yan Y et al (2007) Repairing brain after stroke: A review on post-ischemic neurogenesis. Neurochem Int 50:1028-1041
22. Kneifel S, Bernhardt P, Uusijärvi H et al (2007) Individual voxelwise dosimetry of targeted 90Ylabelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging 34:1388-1395
23. Kneifel S, Cordier D, Good S et al (2006) Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1- glutaric acid-4,7,10triacetic acid-substance P. Clin Cancer Res 12:3843-3850
24. Pollard H, Bouthenet ML, Moreau J et al (1989) Detailed immunoautoradiographic mapping of enkephalinase (EC 3.4.24.11) in rat central nervous system: Comparison with enkephalins and substance P. Neuroscience 30:339-376
25. Tang F, Man WS (1991) The regional distribution of thyrotropin releasing hormone, leu-enkephalin, met-enkephalin, substance P, somatostatin and cholecystokinin in the rat brain and pituitary. Neuropeptides 19:287-292
26. Ray AP, Darmani NA (2007) A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological research. Brain Res 1156:99-111
27. Zohrabian VM, Forzani B, Chau Z et al (2009) Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29:119-123
28. Al-Sarraj A, Thiel G (2002) Substance P induced biosynthesis of the zinc finger transcription factor Egr-1 in human glioma cells requires activation of the epidermal growth factor receptor and of extracellular signal-regulated protein kinase. Neurosci Lett 332:111-114
29. Xu L, Fukumura D, Jain RK (2002) Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: Mechanism of low pH-induced VEGF. J Biol Chem 277:11368-11374
30. Lin HY, Sun M, Tang, HY et al (2009) L-thyroxine vs. 3,5,3'-triiodo-L- thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296:C980-991
31. Zagzag D, Esencay M, Mendez O et al (2008) Hypoxia-and vascular endothelial growth factorinduced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: One plausible explanation of Scherer's structures. Am J Pathol 173:545-560
32. Barbero S, Bonavia R, Bajetto A et al (2003) Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 63:1969-1974
33. Maru SV, Holloway KA, Flynn G et al (2008) Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199:35-45
34. Eyler CE, Rich JN (2008) Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839-2845
35. Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J (2008) Cancer stem cells and brain tumors. Clin Transl Oncol 10:262-267
36. Lefranc F (2009) Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas. Acta Neurochir (Wien) 151:109-112
37. Belda-Iniesta C, de Castro Carpeño J, Sereno M et al (2008) Epidermal growth factor receptor and glioblastoma multiforme: Molecular basis for a new approach. Clin Transl Oncol 10:73-77
38. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E et al (2006) Molecular biology of malignant gliomas. Clin Transl Oncol 8:635-641